{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:30:51Z","timestamp":1793496651546,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ijgc.2025.102124","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T23:06:37Z","timestamp":1756335997000},"page":"102124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Checkpoint inhibitor rechallenge in advanced endometrial cancer: revisiting the immune landscape beyond first-line therapy"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3103-3043","authenticated-orcid":false,"given":"Vivek","family":"Podder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez N.","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1276-6750","authenticated-orcid":false,"given":"Michelle","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6985-0159","authenticated-orcid":false,"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-3096","authenticated-orcid":false,"given":"Brian M.","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ijgc.2025.102124_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"23","key":"10.1016\/j.ijgc.2025.102124_bib2","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102124_bib3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102124_bib4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the Phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102124_bib5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin\u2013paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102124_bib6","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2025.102124_bib7","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.ijgc.2025.102124_bib8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/AOG.0000000000005243","article-title":"Evaluation of efficacy and adverse events after second immunotherapy exposure in endometrial and cervical carcinoma","volume":"142","author":"Morton","year":"2023","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijgc.2025.102124_bib9","article-title":"Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer","volume":"44","author":"Mimura","year":"2022","journal-title":"Gynecol Oncol Rep"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102124_bib10","first-page":"123","article-title":"Activity of pembrolizumab and lenvatinib in mismatch repair deficient EC","volume":"172","author":"Rose","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102124_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004233","article-title":"Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer","volume":"10","author":"Lheureux","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102124_bib12","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1136\/ijgc-2024-005541","article-title":"Real-world use of immune checkpoint inhibitors in advanced or recurrent endometrial cancer","volume":"34","author":"Huepenbecker","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102124_bib13","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ygyno.2019.12.039","article-title":"Second-line lenvatinib in patients with recurrent endometrial cancer","volume":"156","author":"Vergote","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102124_bib14","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/jcm12020603","article-title":"Improved progression-free survival associated with tumor-infiltrating lymphocytes in high-grade endometrial cancer","volume":"12","author":"Fan","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijgc.2025.102124_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.canlet.2021.04.021","article-title":"Emerging immune checkpoints in the tumor microenvironment: implications for cancer immunotherapy","volume":"511","author":"Wei","year":"2021","journal-title":"Cancer Lett"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102124_bib16","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat Med"},{"issue":"6280","key":"10.1016\/j.ijgc.2025.102124_bib17","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102124_bib18","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/ijgc-2022-004026","article-title":"Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer","volume":"33","author":"Hill","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2025.102124_bib19","unstructured":"NRG-GY025 clinical trial protocol. NRG Oncology. Accessed July 18, 2025. https:\/\/www.nrgoncology.org\/Clinical-Trials\/Protocol\/nrg-gy025."},{"key":"10.1016\/j.ijgc.2025.102124_bib20","doi-asserted-by":"crossref","unstructured":"Slomovitz B, Monk B, Moxley K, et al. 348 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12\/NOGGO). Access date July 18, 2025. https:\/\/jitc.bmj.com\/content\/8\/Suppl_3\/A212","DOI":"10.1136\/jitc-2020-SITC2020.0348"},{"issue":"16","key":"10.1016\/j.ijgc.2025.102124_bib21","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med."},{"issue":"17","key":"10.1016\/j.ijgc.2025.102124_bib22","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study","volume":"36","author":"Gettinger","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102124_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2217\/imt-2019-0131","article-title":"Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer","volume":"12","author":"Reinhorn","year":"2020","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102124_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nm.4466","article-title":"High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy","volume":"24","author":"Krieg","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102124_bib25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccell.2016.02.004","article-title":"Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade","volume":"29","author":"Tang","year":"2016","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102124_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1564505","article-title":"Tim-3\/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients","volume":"8","author":"Limagne","year":"2019","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102124_bib27","article-title":"TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM","volume":"7","author":"Hung","year":"2018","journal-title":"Oncoimmunology"},{"issue":"21","key":"10.1016\/j.ijgc.2025.102124_bib28","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1158\/0008-5472.CAN-16-2141","article-title":"Agonistic CD40 mAb-driven IL12 reverses resistance to anti-PD1 in a T-cell-rich tumor","volume":"76","author":"Ngiow","year":"2016","journal-title":"Cancer Res"},{"issue":"32","key":"10.1016\/j.ijgc.2025.102124_bib29","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1016\/j.ijgc.2025.102124_bib30","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"issue":"237","key":"10.1016\/j.ijgc.2025.102124_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci Transl Med"},{"issue":"44","key":"10.1016\/j.ijgc.2025.102124_bib32","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1073\/pnas.1316796110","article-title":"Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans","volume":"110","author":"Sugiyama","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.ijgc.2025.102124_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102124_bib34","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","article-title":"Adenosine Receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses","volume":"3","author":"Beavis","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"536","key":"10.1016\/j.ijgc.2025.102124_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay8456","article-title":"Selective inhibition of TGF\u03b21 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape","volume":"12","author":"Martin","year":"2020","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/j.ijgc.2025.102124_bib36","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"7629","key":"10.1016\/j.ijgc.2025.102124_bib37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102124_bib38","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","article-title":"Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma","volume":"21","author":"Gibney","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"22","key":"10.1016\/j.ijgc.2025.102124_bib39","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J Clin Oncol."},{"issue":"suppl 15","key":"10.1016\/j.ijgc.2025.102124_bib40","doi-asserted-by":"crossref","first-page":"9568","DOI":"10.1200\/JCO.2016.34.15_suppl.9568","article-title":"Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.102124_bib41","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102124_bib42","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102124_bib43","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1659096","article-title":"Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors","volume":"8","author":"Kapp","year":"2019","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102124_bib44","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1038\/s41467-018-06890-y","article-title":"Targeting IFN\u03b1 to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance","volume":"9","author":"Liang","year":"2018","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102124_bib45","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","article-title":"Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade","volume":"2","author":"Cooper","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102124_bib46","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","article-title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","volume":"25","author":"Ribas","year":"2019","journal-title":"Nat Med"},{"issue":"565","key":"10.1016\/j.ijgc.2025.102124_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0391","article-title":"Intratumoral nanoplexed Poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors","volume":"12","author":"M\u00e1rquez-Rodas","year":"2020","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102124_bib48","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102124_bib49","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1158\/1538-7445.AM2025-2894","article-title":"NTX-452: a non-covalent, potent, selective and highly efficacious WRN inhibitor with best-in-class potential for the treatment of MSI-H tumors","volume":"85","author":"Svensson","year":"2025","journal-title":"Cancer Res."},{"issue":"8011","key":"10.1016\/j.ijgc.2025.102124_bib50","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41586-024-07318-y","article-title":"Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase","volume":"629","author":"Baltgalvis","year":"2024","journal-title":"Nature"},{"issue":"7753","key":"10.1016\/j.ijgc.2025.102124_bib51","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41586-019-1102-x","article-title":"WRN helicase is a synthetic lethal target in microsatellite unstable cancers","volume":"568","author":"Chan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ijgc.2025.102124_bib52","unstructured":"ClinicalTrials.gov. A study to evaluate the safety and preliminary efficacy of HRO761 in participants with advanced solid tumors with microsatellite instability. NCT05838768.."},{"issue":"6","key":"10.1016\/j.ijgc.2025.102124_bib53","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102124_bib54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy [published correction in J Hematol Oncol. 2023;16(1):105. doi:10.1186\/s13045-023-01503-8]","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102124_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-39076-8","article-title":"Developing a dual VEGF\/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy","volume":"13","author":"Tzuri","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijgc.2025.102124_bib56","article-title":"Exploring T-cell bispecific antibodies in gynecologic malignancy","volume":"59","author":"O\u2019Brien","year":"2025","journal-title":"Gynecol Oncol Rep"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25012447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25012447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:26:47Z","timestamp":1793496407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25012447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1048891X25012447"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102124","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Checkpoint inhibitor rechallenge in advanced endometrial cancer: revisiting the immune landscape beyond first-line therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102124"}}